Neon Therapeutics Inc. (NTGN) and Intec Pharma Ltd. (NASDAQ:NTEC) Contrasting side by side – The FinExaminer

As Biotechnology companies, Neon Therapeutics Inc. (NASDAQ:NTGN) and Intec Pharma Ltd. (NASDAQ:NTEC) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neon Therapeutics Inc.N/A0.0077.55M-2.750.00
Intec Pharma Ltd.N/A0.0043.54M-1.400.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Neon Therapeutics Inc. and Intec Pharma Ltd.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net MarginsReturn on EquityReturn on Assets
Neon Therapeutics Inc.0.00%-545.4%-69.6%
Intec Pharma Ltd.0.00%0%0%

Institutional & Insider Ownership

Neon Therapeutics Inc. and Intec Pharma Ltd. has shares held by institutional investors as follows: 70.1% and 39.64%. About 16.29% of Neon Therapeutics Inc.’s share are held by insiders. Comparatively, Intec Pharma Ltd. has 11.81% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W)Performance (M)Performance (Q)Performance (HY)Performance (Y)Performance (YTD)
Neon Therapeutics Inc.22.03%47.64%1.29%-45.99%0%24.45%
Intec Pharma Ltd.-5.95%4.85%37.69%116.32%34.75%9.02%

For the past year Neon Therapeutics Inc. was more bullish than Intec Pharma Ltd.


On 4 of the 6 factors Intec Pharma Ltd. beats Neon Therapeutics Inc.

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.